Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors

NCT05196308 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

226

Enrollment

OTHER

Sponsor class

Conditions

Erectile Dysfunction

Interventions

DRUG: Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
DRUG: Placebo administration

Sponsor

Assistance Publique - Hôpitaux de Paris